Summary Flow cytometric studies of T-lymphocytes 
Ferritin is generally regarded as an iron storage protein, the small amount of ferritin normally present in serum reflecting the level of storage iron in the body Worwood, 1982) . Elevated levels of serum ferritin are found in iron overload states but have also been described in many malignant diseases (Jacobs, 1984) . Some authors have linked the high serum ferritin concentrations in cancer patients to a variety of immunosuppressive effects involved in cellular immunity (Levy & Kaplan, 1974; Matzner et al., 1979; Hancock et al., 1979) . There is evidence for a subpopulation of lymphocytes from the peripheral blood of patients with breast cancer and Hodgkin's disease which bears surface membrane ferritin (Moroz et al., 1977a,b) , and it has been suggested that this may be responsible for a suppressive effect on T-cell function.
It is known that the raised concentration of ferritin found in serum from patients with leukaemia (Worwood et al., 1974; Parry et al., 1975 ) and Hodgkin's disease (Sarcione et al., 1977) is associated with an increased concentration of ferritin in circulating leukocytes. Cragg et al. (1984) showed that the majority of monocytes and B lymphocytes in normal peripheral blood have a significant amount of surface ferritin, whereas only a small fraction of T-cells had ferritin on their surface. The presence of surface ferritin on only a minor fraction of T-cells is unlikely to be due to a difference in endogenous production as T-cell ferritin synthesis is greater than that of B cells (Dorner et al., 1980) . The presence of B-cell surface ferritin is compatible with the suggestion that the protein may play a part in determining lymphocyte movement in the body (de Sousa et al., 1978) .
A number of studies show a good relationship between the development of cancer and increased lymphocyte-bound ferritin (Moroz et al., 1984; Bluestein et al., 1984; Jacobs et al., 1984) and there is a potential diagnostic and prognostic value of enumerating ferritin-bearing lymphocytes in breast cancer patients. However, it is not clear whether ferritin present on the surface of lymphocytes in cancer patients is a specific binding of ferritin to the lymphocyte surface associated with a high circulating ferritin concentration, or if it has a more specific significance. Following mitogen stimulation there is a marked increase in the number of T-cells bearing ferritin on their surface membrane and this coincides with an increase in other proliferative markers (Pattanapanyasat et al., 1987) . (Ali et al., 1982) , and centrifuged at 400g for 30min. The (Jones & Worwood, 1978) . Both the anti-spleen and anti-heart ferritin used were immunoglobulin fractions obtained from sodium sulphate precipitation of antiserum (Conradie & Mbhele, 1980) . Streptavidin-FITC (Amersham), biotinyl-N-hydroxysuccinimide (BNHS) , N,N-dimethylformamide (DMF), sheep and rabbit immunoglobulin (Sigma) were also used.
Biotinylation offerritin antibody (Guesdon et al., 1979) Five mg of either spleen or heart ferritin antibody was dissolved in 1 ml of sodium bicarbonate pH 8.0, incubated with 125 pl BNHS (8 mg BNHS in 1 ml DMF) for 2 h at room temperature and dialysed overnight at 40C against several changes of PBS. After centrifugation at 500 g for 10 min the supernatant was added to an equal volume of glycerol and kept at -20°C until required.
Determination of ferritin-bearing T-lymphocytes This was performed by a dual immunofluorescence technique using the biotin-streptavidin system (Pattanapanyasat et al., 1987 (Worwood, 1980 
Serum ferritin concentration
The mean serum ferritin concentration in 50 cancer patients was significantly higher (P <0.05) than in normal subjects or those with benign breast disease (Figure 1) , despite a wide variation in the results and the presence of a well defined group with pathologically low serum ferritin concentration, presumably due to coexistent iron deficiency. However, there was no statistically significant difference between cancer patients with different disease staging.
Expression of T-lymphocyte surface ferritin The number of ferritin-bearing T-cells in different groups of subjects are shown in Figures 2 and 3 . The mean percentage of spleen ferritin-bearing T-cells in 50 patients with breast cancer was significantly higher (P<0.001) than in normal controls. However, there was no significant difference between the levels in normal controls and patients with either benign breast disease or iron deficiency anaemia. It is interesting that two homozygous beta-thalassaemic patients, whose serum ferritin concentrations were > 1700 pg 1-1 showed a low percentage of ferritin-bearing T-cells. Patients with benign inflammatory disease have a higher number of ferritin-positive cells than those with non-inflammatory disease.
The mean percentage of heart ferritin-bearing T-cells in 30 cancer patients was higher (P<0.001) than the mean from 8 normal subjects (Figure 3 ). However, there was no statistical difference between the patients with cancer and benign disease. The bimodal distribution of serum ferritin levels in cancer patients is not reflected by a similar bimodality in the number of ferritin-positive lymphocytes.
Percentage offerritin-bearing T-cells, disease stages and serum ferritin levels In order to assess the value of ferritin-positive T-cells as a diagnostic tool, a normal upper cut-off of 7.0% for spleen ferritin and 7.8% for heart ferritin-bearing T-cells was used, these being the 95% confidence limits for the normal group. Only 2 out of 20 normal subjects (10%) had higher levels of spleen ferritin-bearing (Table I) . Other T-cell surface antigens Measurement of Tac and transferrin receptors on T-cells in normal subjects and patients with breast disease showed no significant difference in their levels, whereas in cancer patients 13.4 + 6.0% of T-cells were HLA-DR positive compared to 5.4+7.5% in normal subjects (P<0.01) and 11.5 + 5.0% in patients with benign breast disease (NS) (data not shown). There was no significant difference in total Tcells, T-helper or B-cells between normal and breast disease patients. However, T-suppressor cells in cancer patients (23.6 + 5.9%) were significantly increased (P < 0.001) compared to either normal subjects (18.9 + 9.0%) or patients with benign breast disease (17.5 + 7.3%) (data not shown).
Discussion
In this study serum ferritin concentrations in normal subjects and patients with iron deficiency or overload are similar to those found previously (Jacobs et al., 1972; Worwood, 1982) . It also confirms other earlier reports (Marcus & Zinberg, 1975; Jacobs et al., 1976) of high circulating ferritin levels in patients with breast cancer. There are many possible causes of raised serum ferritin levels in malignancy, including increased iron stores, release of ferritin from inflamed tissues and production of ferritin by proliferating tumour cells . Although it is tempting to consider it as a tumour associated protein, the reason is still far from clear (Jacobs, 1984) . Measurement of T-lymphocyte surface ferritin shows that the mean percentage of ferritin-positive T-cells in breast cancer patients is significantly higher than in normal subjects and in patients with benign breast disease. Seventy to eighty percent of cancer patients have an increased percentage of ferritin-bearing T-cells, compared to less than 10% in the (Moroz et al., 1984; Bluestein et al., 1984) and other malignant diseases (Bluestein et al., 1984; Steinhoff et al., 1984; Papenhausen et al., 1984) . Of greater importance is the correlation between ferritinbearing lymphocytes and the clinical stage of the disease; unfortunately there is some disagreement in this area. Moroz et al. (1984) found that the level of ferritin-positive cells in breast cancer patients was elevated in stages I, II and IV, but low in stage III. In our study, although there is a significant increase in spleen ferritin-bearing T-cells in all stages of breast cancer, this does not appear to be related to disease stage (Figure 2 ). However, there is an increased level in only 61% of stage III patients compared to stage I (76%), stage II (100%) and stage IV (100%). Moroz et al. (1984) hypothesised that this rather surprising finding in stage III patients may be due to deranged traffic of ferritin-bound lymphocytes, which accumulate at an extravascular site to be replaced in the blood by other lymphocytes, as suggested by the studies of De Sousa et al. (1978) . Jacobs et al. (1984) found an elevated level of spleen ferritin-bearing lymphocytes in patients with Hodgkin's disease, but no relationship to disease stage. A similar result has also been reported in patients with head and neck cancer (Papenhausen et al., 1984) .
Spleen ferritin-positive T-cells show no significant difference between the normal controls, patients with benign breast lesion, patients with iron deficiency anaemia and patients with idiopathic haemochromatosis. Although 8 out of 20 patients with benign breast disorders show elevated levels of T-cells bearing spleen ferritin, 6 of these are of an inflammatory type and the phenomenon may be a result of T-cell activation (Pattanapanyasat et al., 1987) . This could also explain the increased number of HLA-DR positive cells in breast cancer patients.
This study shows that there are zero or low Tac-positive and transferrin receptor-positive T-cells in breast cancer patients. It is known that T-cell proliferation is dependent on the presence of Tac antigen (Uchiyama et al., 1981) , transferrin receptor (Larrick & Cresswell, 1979) , and HLA-DR antigen (Ko et al., 1979) and that resting T-cells possess few of these molecules. It is unusual to see an increase in the level of HLA-DR positive T-cells unrelated to other proliferative markers, but it may simply be that the degree of HLA-DR positivity found here is a response to mild stimulation and is certainly not comparable to that seen in mitogen stimulated T-cells (Ko et al., 1979; Pattanapanyasat et al. 1987) where levels are 5-6 times higher than in normal T-cells.
Similarly, heart ferritin-bearing T-cells show no relationship with the clinical disease stage. Measurements of T-cells bearing either spleen or heart ferritin do not appear to discrminate between the clinical stage of breast cancer. However, it is able to differentiate, to some extent, between patients with benign breast disease and patients with breast carcinoma, or between normal and cancer patients and it might help in identifying some patients with inflammatory or premalignant breast lesions.
It has been suggested that ferritin may play a crucial role in suppressing normal T-cell function (Matzner et al., 1979; Hancock et al., 1979) . Our results show no correlation between T-cells bearing ferritin and serum ferritin concentration. This suggests that the increased number of T-cells bearing ferritin is not secondary to high circulating levels. Moreover, a low percentage of T-cells bearing ferritin has been demonstrated in both patients with homozygous betathalassaemia and hyperferritinaemia. Moroz et al. (1977b) found 4 patients with thalassaemia to be devoid of ferritinbearing lymphocytes. Recently, Steinhoff et al. (1984) studied lymphocyte surface ferritin in patients known to have high levels of serum ferritin, such as haemochromatotic patients, patients with rheumatoid arthritis and patients with bacterial infection. None of them had elevated levels of lymphocytebearing ferritin.
At present, the precise subset of lymphocytes in breast cancer patients to which the ferritin-bearing lymphocytes belong is unknown. Cragg et al. (1984) showed that a minor fraction of both T-helper and T-suppressor cells have surface ferritin. In addition, our results show that the level of peripheral blood T-suppressor cells in patients with breast cancer is higher than that of normal subjects, though whether there is any connection with an increase in ferritinbearing T-cells is not clear.
Although the functional significance of this phenomenon is unknown, it may prove to be another useful indicator of the presence of malignancy along with other tumour markers.
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